Ilya Pharma, being a clinical stage biopharmaceutical development company is currently pursuing three projects with drug candidates from its proprietary ILP-technology platform to clinical proof of concept and validation.
The innovation stems from cutting edge medical research in immunophysiology and applied microbiology at Uppsala University and the Swedish University of Agricultural Sciences. The treatments target the function of tissue-resident immune cells. The mechanism of action for the first project of accelerated healing in skin wounds was published in PNAS 2018.
- Invested amount
EUR 3 484 426